Navigating Pharmacogenomic Testing in Practice: Who to Test and When to Test
Clinical Pharmacology & Therapeutics · 2025-09 · 118 (3) · 561-566
DOI: 10.1002/cpt.3704 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 05.05.2025. Verfasst von James M Stevenson und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmacology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Pharmacogenomic Testing, Pharmacogenetics, Precision Medicine. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
There is increasing attention on the clinical utility and value of pharmacogenetic (PGx) testing to individualize medication management. Most clinical practice guidelines from medical professional societies do not recommend routine PGx testing, with a few key exceptions. Inconsistent recommendations across clinical practice guidelines, FDA product labeling, and payer reimbursement policies have hampered widespread adoption of testing. Multiple resources exist to aid in the adoption and use of actionable PGx test results in clinical practice; however, most of these resources do not provide guidance on who should receive PGx testing and when—a critical question the clinical community continues to struggle with. There are multiple considerations when answering this question beyond the clinical validity of the drug–gene interaction itself, such as the actionable result frequency, severity of the adverse clinical outcome, predictive power of the PGx test, suitability of alternative treatments, cost, and turnaround time of test results. This perspective discusses these considerations and models for testing including preemptive screening, pretreatment testing, and reactive testing, highlighting advantages and disadvantages of each approach. The authors provide their perspectives on identifying candidates for PGx testing in the current real‐world environment and how that differs from a clinically ideal scenario.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Clinical Pharmacology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- MedStar Health, Columbia, Maryland, USA.
- Department of Oncology, Georgetown University Medical Center, Washington, DC, USA.
- Division of Translational Medicine and Human Genetics, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Division of Cancer Pharmacology & Pharmacogenomics, Atrium Health Levine Cancer, Charlotte, North Carolina, USA.
ORCID-Profile: James M Stevenson, D Max Smith, Sony Tuteja, Jai N Patel
Zitieren
APA
Stevenson, J. M., Smith, D. M., Tuteja, S., Patel, J. N., & Pharmacogenomics Global Research Network (PGRN) Publications Committee (2025). Navigating Pharmacogenomic Testing in Practice: Who to Test and When to Test. Clinical Pharmacology & Therapeutics, 118(3), 561-566. https://doi.org/10.1002/cpt.3704
Vancouver
Stevenson JM, Smith DM, Tuteja S, Patel JN, Pharmacogenomics Global Research Network (PGRN) Publications Committee. Navigating Pharmacogenomic Testing in Practice: Who to Test and When to Test. Clinical Pharmacology & Therapeutics. 2025;118(3):561-566. doi:10.1002/cpt.3704
BibTeX
@article{Stevenson2025,
author = {Stevenson, James M and Smith, D Max and Tuteja, Sony and Patel, Jai N and Pharmacogenomics Global Research Network (PGRN) Publications Committee, Pharmacogenomics Global Research Network (PGRN) Publications Committee},
title = {Navigating Pharmacogenomic Testing in Practice: Who to Test and When to Test},
journal = {Clinical Pharmacology & Therapeutics},
year = {2025},
volume = {118},
number = {3},
pages = {561--566},
doi = {10.1002/cpt.3704}
}
EUVIMED